A cost effectiveness analysis of solifenacin compared with extended-release tolterodine for the treatment of overactive bladder

被引：0
|
作者：
Kang, H. H. [1 ]
Bae, J. Y. [1 ]
Park, S. Y. [1 ]
Sohn, H. S. [1 ]
机构：
[1] Sock Myung Womens Univ, Seoul, South Korea
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65151-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A319 / A319
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
    Xie, J.
    Zhou, Z. Y.
    Bui, C. N.
    Yan, Y.
    De, G.
    Runken, M. C.
    Wu, E. Q.
    VALUE IN HEALTH, 2012, 15 (07) : A457 - A457
  • [22] Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder
    Getsios, D
    Caro, JJ
    Ishak, KJ
    El-Hadi, W
    Payne, K
    CLINICAL THERAPEUTICS, 2004, 26 (03) : 431 - 438
  • [23] Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET)
    Sussman, D
    Garely, A
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) : 177 - 184
  • [24] Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder
    Kreder, K
    Mayne, C
    Jonas, U
    EUROPEAN UROLOGY, 2002, 41 (06) : 588 - 595
  • [25] The cost-effectiveness of extended release tolterodine in the management of overactive bladder in Germany and the United Kingdom
    Anderson, P
    Resch, A
    Dooley, JA
    Brüggenjürgen, B
    Zlateva, G
    VALUE IN HEALTH, 2004, 7 (06) : 797 - 798
  • [26] Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia
    Nitti, Victor W.
    Dmochowski, Roger
    Appell, Rodney A.
    Wang, Joseph T.
    Bavendam, Tamara
    Guan, Zhonghong
    BJU INTERNATIONAL, 2006, 97 (06) : 1262 - 1266
  • [27] Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms
    Ho, Chen-Hsun
    Chang, Ting-Chen
    Lin, Ho-Hsiung
    Liu, Shih-Ping
    Huang, Kuo-How
    Yu, Hong-Jeng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (10) : 702 - 708
  • [28] Cost-Effectiveness of Percutaneous Tibial Nerve Stimulation Versus Extended Release Tolterodine for Overactive Bladder
    Chen, Heidi W.
    Bercik, Richard S.
    Werner, Erika F.
    Thung, Stephen F.
    JOURNAL OF UROLOGY, 2012, 187 (01): : 178 - 184
  • [29] The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder
    Dmochowski, Roger
    Kreder, Karl
    MacDiarmid, Scott
    Carlsson, Martin
    Guan, Zhonghong
    BJU INTERNATIONAL, 2007, 100 (01) : 107 - 110
  • [30] Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence
    Roehrborn, Claus G.
    Abrams, Paul
    Rovner, Eric S.
    Kaplan, Steven A.
    Herschorn, Sender
    Guan, Zhonghong
    BJU INTERNATIONAL, 2006, 97 (05) : 1003 - 1006
12345